<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10970701</article-id><article-id pub-id-type="pmc">2374693</article-id><article-id pub-id-type="pii">6691382</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title><italic>Haemophilus influenzae</italic> type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Auvinen</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hakulinen</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Groves</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>STUK &#x02013; Radiation and Nuclear Safety Authority, P.O. Box 14, Helsinki, FIN-00881, Finland</aff><aff id="aff2"><label>2</label>School of Public Health, University of Tampere, Tampere, FIN-33014, Finland</aff><aff id="aff3"><label>3</label>Finnish Cancer Registry, Liisankatu 21 B, Helsinki, FIN-00170, Finland</aff><aff id="aff4"><label>4</label>Department of Public Health, University of Helsinki, P.O. Box 441, Helsinki, FIN-00014, Finland</aff><aff id="aff5"><label>5</label>Department of Biometry and Epidemiology, Medical University of South Carolina, P.O. Box 250551, Charleston, SC 29425, USA</aff><pub-date pub-type="epub"><day>04</day><month>09</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2000</year></pub-date><volume>83</volume><issue>7</issue><fpage>956</fpage><lpage>958</lpage><history><date date-type="received"><day>14</day><month>02</month><year>2000</year></date><date date-type="rev-recd"><day>13</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>08</day><month>06</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Incidence of childhood leukaemia was studied among subjects of a trial comparing administration of several doses of a conjugate vaccine against <italic>Haemophilus influenzae</italic> type b (Hib) starting at an early age (three months) with a single dose given at the age of two years. Among 114 000 subjects, a total of 77 cases of childhood leukaemia were detected. The incidence of childhood leukaemia was lower in the early vaccination arm (relative risk 0.72, 95&#x00025; confidence interval 0.46&#x02013;1.13) than late vaccination arm, but the difference did not reach statistical significance. Our results suggest that early immunization against Hib may reduce the incidence of childhood leukaemia, but confirmatory studies are needed. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>leukaemia</kwd><kwd>child</kwd><kwd>vaccinations</kwd><kwd><italic>Haemophilus influenzae</italic> type b</kwd><kwd><italic>Haemophilus influenzae</italic> type b polysaccharide vaccine diphtheria toxoid conjugate</kwd><kwd>clinical trials</kwd></kwd-group></article-meta></front></article>


